SPDR S&P Pharmaceuticals ETF (XPH) - NYSEARCA
  • Oct. 13, 2015, 3:49 PM
    • Getting out in front of what should be more bashing of their business models at the Democratic debate tonight, the healthcare names (XLV -1.3%) have about doubled the decline in the S&P 500. Within healthcare, it's the biotechs (IBB -3.1%) and pharmaceuticals (XPH -3.2%) leading the way south.
    • Celgene (CELG -3.3%), Biogen (BIIB -3.6%), Amgen (AMGN -3.5%), Allergan (AGN -4.1%), Mylan (MYL -3.6%)
    • The biotech heavy Russell 2000 (IWM -1.4%) is feeling the pain as well.
    • ETFs: IBB, IYH, XLV, XBI, VHT, PJP, BBH, FBT, HQH, CURE, XPH, HQL, PBE, FXH, RXL, IHE, FHLC, SBIO, PPH, RYH, BBC, THQ, BBP, RXD, LABU, LABD, UBIO, ZBIO
    | Oct. 13, 2015, 3:49 PM | 27 Comments
  • Sep. 28, 2015, 12:50 PM
    | Sep. 28, 2015, 12:50 PM | 24 Comments
  • Sep. 25, 2015, 3:07 PM
    | Sep. 25, 2015, 3:07 PM | 134 Comments
  • Apr. 4, 2014, 1:12 PM
    | Apr. 4, 2014, 1:12 PM | 6 Comments
  • May 6, 2013, 1:36 PM

    Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses.

    | May 6, 2013, 1:36 PM
  • Sep. 23, 2011, 1:53 PM

    Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy.

    | Sep. 23, 2011, 1:53 PM | 1 Comment
  • Aug. 24, 2011, 3:06 PM

    More on Allergan (AGN +2.4%): Shares started trading higher yesterday in advance of today's announcement the firm's BOTOX solution was approved by the FDA.

    | Aug. 24, 2011, 3:06 PM
  • Aug. 24, 2011, 8:45 AM

    United Therapeutics (UTHR) falls sharply after disclosing its late-stage drug for pulmonary arterial hypertension failed to improving walking distance for patients. The firm says it will still move forward to seek FDA approval based on an earlier positive study. Shares down 21% premarket.

    | Aug. 24, 2011, 8:45 AM
  • Aug. 24, 2011, 8:14 AM

    Elan (ELN) is up 5.2% premarket after Credit Suisse weighs in with an upgrade to Outperform from Neutral.

    | Aug. 24, 2011, 8:14 AM
  • Aug. 22, 2011, 11:23 AM

    Vertex Pharmaceuticals (VRTX -2.5%) spikes lower after the firm announces it has received approval from Health Canada for its liver disease tablets. Shares were initially up 3% after the opening, before taking a nosedive.

    | Aug. 22, 2011, 11:23 AM | 1 Comment
  • Aug. 5, 2011, 1:33 PM

    Shares of OncoGeneX (OGXI -24.3%) crater after the firm announces two of its drug-development programs for lung cancer will have delayed results. Interestingly, the share price started falling yesterday in advance of this morning's announcement.

    | Aug. 5, 2011, 1:33 PM | 1 Comment
  • Aug. 1, 2011, 12:11 PM

    Jazz Pharmaceuticals (JAZZ +2.8%) posts another gain after Friday's big post-Q2 earnings report jump. Jefferies upgrades shares to a Buy from Hold with a $52 price target noting the firm "previously modeled only 5% volume growth in '11-'13," but now sees "double-digit growth."

    | Aug. 1, 2011, 12:11 PM
  • Aug. 1, 2011, 8:37 AM

    Elan (ELN) shares jump +4.6% premarket after Acorda Therapeutics (ACOR) announces positive prescriber response for its AMPYRA treatment for MS patients. The drug is manufactured by Elan in a supply agreement with Acorda.

    | Aug. 1, 2011, 8:37 AM
  • Jul. 21, 2011, 12:25 PM

    Shares of Alexion (ALXN +8.7%) pop after issuing upward guidance, and announcing it plans to launch its Soliris treatment for patients with aHUS in Q4. (PR)

    | Jul. 21, 2011, 12:25 PM
  • Jul. 21, 2011, 8:20 AM

    Shares of Protalix (PLX) +4.4% premarket after a report says the firm will file a request with the FDA within days for approval of the firm's Gaucher's disease treatment Uplyso.

    | Jul. 21, 2011, 8:20 AM
  • Jul. 12, 2011, 3:48 PM

    Shares of Infinity Pharmaceuticals (INFI +9.6%) pop on above-average volume as the company expands its program to develop new cancer drugs, buying nuisance weeds in western states, unwanted by landowners, but needed by the firm.

    | Jul. 12, 2011, 3:48 PM
XPH Description
The SPDR® S&P® Pharmaceuticals ETF seeks to replicate as closely as possible, before expenses, the total return performance of the S&P Pharmaceuticals Select Industry® Index. Our approach is designed to provide portfolios with low portfolio turnover, accurate tracking, and lower costs.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub